Advice

following a full submission

dabrafenib (Tafinlar) is accepted for use within NHSScotland.

Indication under review: In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

Relapse-free survival was significantly longer in the dabrafenib plus trametinib group compared with placebo in a phase III study of patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations.

This SMC advice takes account of the benefits of a Patient Access Schemes (PAS) that improves the cost-effectiveness of dabrafenib and trametinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Medicine details

Medicine name:
dabrafenib (Tafinlar)
SMC ID:
SMC2131
Indication:
In combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
11 February 2019